30 March - 5 April 2019
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.
Mavenclad (cladribine) approved in USA
Mavenclad (cladribine) has been approved by the FDA, the US drug regulator, for relapsing forms of MS, including relapsing remitting MS and “active” secondary progressive MS. In the UK, Mavenclad has been approved as an NHS treatment since 2017.
MS Trust link: Mavenclad
Gabapentin and pregabalin reclassified
From April 1, gabapentin and pregabalin have been reclassified as controlled drugs. This has resulted in changes to how they are prescribed, particularly for repeat prescriptions.
MS Trust link: Gabapentin and pregabalin - new rules for prescriptions
Receiving an MS diagnosis during my gender transition
22 Feb 2021 - 00:00
Chris shares his experience of being diagnosed with MS at the same time as starting hormone treatment and a surgical gender transition.
David's Diary- Should we all be saying yes to the Covid 19 vaccine?
18 Feb 2021 - 00:00
For the last few weeks our Enquiry Service at the MS Trust has been busy with questions about the vaccination. In his latest blog piece for the MS Trust, CEO David Martin asks the question, 'Should we all be saying yes to the Covid 19 vaccine?'
Monkey sox are back!
17 Feb 2021 - 00:00
...but this time they've gone casual! We are very excited to have partnered once again with Monkey Sox to bring you an exclusive MS Trust design.